Literature DB >> 34929156

The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-Bearing Mice.

Jamie L Betker1, Thomas J Anchordoquy2.   

Abstract

It is becoming increasingly clear that the intravenous administration of nanoparticles elicits an immune response that compromises delivery efficiency and can be life threatening. This study investigated both the systemic and tissue-level cytokine response to repeat administration of lipoplexes coated with either lactose or PEG. We report that blood cytokine levels differ significantly from that observed in individual tissues. While we consistently observed a reduced cytokine response to lactosylated particles, this did not result in enhanced delivery or expression as compared to PEGylated formulations. We also document that repeat injection did not increase plasmid levels in the liver, lung, or spleen, but delivery to the tumor was enhanced under these conditions. In addition, we show that changes in neither blood nor tissue cytokines correlated strongly with reporter gene expression, and we observed relatively constant expression efficiencies (RLU/ng plasmid) across all tissues despite a considerably reduced cytokine response in the tumor. Together, these results indicate that both biodistribution and cytokine responses are dramatically altered by a repeat intravenous injection of lipoplexes, and that the mechanisms regulating reporter gene expression are not straightforward.
Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Cationic lipid; DNA delivery; Immune response; Lipid nanoparticle; Lipoplex; Non-viral gene delivery; Pegylation; Plasmid DNA; Transfection

Mesh:

Substances:

Year:  2021        PMID: 34929156      PMCID: PMC9206043          DOI: 10.1016/j.xphs.2021.12.017

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.784


  70 in total

Review 1.  Overcoming tumor-mediated immunosuppression.

Authors:  Hans Anton Schlößer; Sebastian Theurich; Alexander Shimabukuro-Vornhagen; Udo Holtick; Dirk Ludger Stippel; Michael von Bergwelt-Baildon
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

2.  Hypersensitivity and loss of disease site targeting caused by antibody responses to PEGylated liposomes.

Authors:  Adam Judge; Kevin McClintock; Janet R Phelps; Ian Maclachlan
Journal:  Mol Ther       Date:  2005-11-07       Impact factor: 11.454

3.  Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice.

Authors:  Jamie L Betker; Thomas J Anchordoquy
Journal:  J Pharm Sci       Date:  2016-11-22       Impact factor: 3.534

4.  Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity.

Authors:  Peng Zhang; Fang Sun; Caroline Tsao; Sijun Liu; Priyesh Jain; Andrew Sinclair; Hsiang-Chieh Hung; Tao Bai; Kan Wu; Shaoyi Jiang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-14       Impact factor: 11.205

5.  Immunogenicity and rapid blood clearance of liposomes containing polyethylene glycol-lipid conjugates and nucleic Acid.

Authors:  Sean C Semple; Troy O Harasym; Kathy A Clow; Steven M Ansell; Sandra K Klimuk; Michael J Hope
Journal:  J Pharmacol Exp Ther       Date:  2004-11-03       Impact factor: 4.030

6.  Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.

Authors:  Jamie L Betker; Dallas Jones; Christine R Childs; Karen M Helm; Kristina Terrell; Maria A Nagel; Thomas J Anchordoquy
Journal:  J Control Release       Date:  2018-07-17       Impact factor: 9.776

Review 7.  Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.

Authors:  Alberto Gabizon; Hilary Shmeeda; Yechezkel Barenholz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex.

Authors:  Eman Alaaeldin; Amr S Abu Lila; Naoto Moriyoshi; Hatem A Sarhan; Tatsuhiro Ishida; Khaled A Khaled; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2013-05-15       Impact factor: 4.200

9.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

Authors:  A Gabizon; D Papahadjopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

10.  In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation.

Authors:  Ye Zhang; Erica L Bradshaw-Pierce; Alexandra Delille; Daniel L Gustafson; Thomas J Anchordoquy
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

View more
  1 in total

Review 1.  Cytokine Responses to Adenovirus and Adenovirus Vectors.

Authors:  Svetlana Atasheva; Dmitry M Shayakhmetov
Journal:  Viruses       Date:  2022-04-24       Impact factor: 5.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.